OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Delayed Deutsche Boerse AG 14:31:00 17/05/2024 BST | ||
| 2.5 EUR | +2.04% |
|
| Current month | -6.13% | ||
| 1 month | -37.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 2.5 | +2.04% |
| 16/05/24 | 2.45 | +1.24% |
| 15/05/24 | 2.42 | +8.52% |
| 14/05/24 | 2.23 | -1.76% |
| 13/05/24 | 2.27 | +1.79% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 02:31 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SH8MDE |
| ISIN | DE000SH8MDE4 |
| Date issued | 11/04/2022 |
| Strike | 14,260 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.3 € |
|---|---|
| Lowest since issue | 2.16 € |
| Spread | 0.01 € |
| Spread % | 0.40% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
154.2
USD
Average target price
167.6
USD
Spread / Average Target
+8.70%
- Stock Market
- Certificates
- Certificat
